Nanoform, AstraZeneca Commence Technology Evaluation

September 27, 2019

Nanoform and AstraZeneca have agreed to start a technology evaluation of Nanoform’s CESS Technology across a range of AstraZeneca’s pharmaceutical products.

Nanoform and AstraZeneca have agreed to start a technology evaluation of Nanoform’s CESS Technology across a range of AstraZeneca’s pharmaceutical products, it was unveiled in a Sep. 25, 2019 press release.

The CESS (Controlled Expansion of Supercritical Solutions) technology is capable of producing nanonized API particles as small as 10 nm, which is useful in progressing poorly soluble molecules into clinical development. This technology evaluation agreement between Nanoform and AstraZeneca will assess the added value that CESS technology may be able to deliver across the pharmaceutical supply chain.

“We have always believed that our technology has significant value to offer the pharma industry, particularly in reducing clinical attrition rates by nanonization to increase dissolution rates of poorly soluble APIs and overcome significant bioavailability challenges, as evidenced by the work conducted between us and our pharmaceutical partners,” said Edward Hæggström, CEO of Nanoform, in the press release. “Producing tailored nanoparticles <200 nm from solution, in a controlled and reproducible manner, with good yield and without the need for excipients is highly challenging to do by current pharmaceutical manufacturing techniques or processes. This [technology evaluation] is the first step of hopefully a long and successful relationship between our two companies and we look forward to working closely with AZ to support their early development needs and validating the value of our technology for their products.”

Source: Nanoform